RecruitingNot ApplicableNCT06845501

Purine Supplementation in Patients With AICA-Ribosiduria

PURICA : Purine Supplementation in Patients With AICA-Ribosiduria


Sponsor

Centre Hospitalier Universitaire de Saint Etienne

Enrollment

10 participants

Start Date

Apr 24, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

AICA-Ribosiduria due to ATIC deficiency is a rare genetic metabolic disease that affects less than 10 patients (PMID: 32557644). It results in severe polyhandicap linked to neurodevelopmental disorders, visual impairment, growth retardation, severe spinal deformities and scoliosis, and often early-onset epilepsy. The disease is caused by dysfunction of the ATIC enzyme, which is involved in de novo purine biosynthesis. A recent study (PMID: 38244287) reported a decrease in disease biomarkers in a single patient after 3 months on a purine-rich diet, which persisted for at least 1 year. The investigators propose to replicate this study on several patients to investigate the potential of this treatment for this severe orphan disease.


Eligibility

Min Age: 3 Years

Inclusion Criteria1

  • Individual affected by AICA-ribosiduria due to ATIC deficiency

Exclusion Criteria1

  • \- Individual already on a purine-rich diet theoretical contraindication to a purine-rich diet

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTpurine-rich diet

diet to achieve a purine intake of 160mg/d


Locations(1)

Chu Saint-Etienne

Saint-Etienne, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06845501